"Lazarus Response" When Feto-Maternal Microchimerism Kicks in: Spontaneous Remission in Refractory Primary Mediastinal B Cell Lymphoma Following Twin Pregnancy

Diagnostics (Basel). 2024 Sep 20;14(18):2084. doi: 10.3390/diagnostics14182084.

Abstract

Background: Spontaneous remission of cancer is a rare and poorly understood phenomenon characterized by complete or partial remission of a malignancy in the absence of or with inadequate treatment. The underlying mechanism for such occurrences is poorly understood, however, immune mechanisms seem to play an important role in such cases. In recent years increasingly more data have become available in favor of the clinical benefit of low levels of chimerism in hematologic malignancies. One such instance of naturally occurring low-level chimerism is feto-maternal microchimerism which has been shown to influence cancer progression and, in some instances, to be a protective factor against malignancy. Case report: We report a case of a young female patient with aggressive primary mediastinal large B cell lymphoma refractory to two lines of chemo-immunotherapy achieving sustained complete metabolic remission of tumor while pregnant with twins. Results: A focus on feto-maternal microchimerism during and after pregnancy revealed transient levels of feto-maternal microchimerism in the peripheral blood of the patient as measured by quantifying the Y-chromosome-linked SRY gene. Conclusions: Microchimerism presents significant potential for enhancing our comprehension of disease mechanisms, uncovering novel therapeutic targets, and refining diagnostic and treatment approaches, especially concerning cancer.

Keywords: SRY; gene analysis; microchimerism; remission.

Publication types

  • Case Reports

Grants and funding

R.A.T. is funded by an internal grant of the Iuliu Hatieganu University—School of Doctoral Studies (PCD 2024-2026). C.T. is funded by an international grant of the European Hematology Association (EHA-SWG Immunotherapy Project 2024—CAR NK cells for tumor associated macrophage immunomodulation—a new era of immunotherapy), as well as by a bilateral collaboration grant between Romania and Moldova (PN-IV-P8-8.3-ROMD-2023-0036), with S.B. C.T. is also funded by a national grant of the Romanian Research Ministry—PNRR 2024–2026 (PNRR/2022/C9/MCID/18, Contract No. 760278/26.03.2024).